David Hessl1,2, Jim Grigsby3. 1. a MIND Institute , University of California Davis Medical Center , Sacramento , CA , USA. 2. b Department of Psychiatry and Behavioral Sciences , University of California Davis , Sacramento , CA , USA. 3. c Department of Psychology and Medicine , University of Colorado Denver , Denver , CO , USA.
Abstract
OBJECTIVE: Neuropsychologists have an important role in evaluating patients with fragile X-associated disorders, but most practitioners are unaware of the recently identified neurodegenerative movement disorder known as fragile X-associated tremor ataxia syndrome (FXTAS). The objective of this editorial is to orient the reader to FXTAS and highlight the importance of clinical neuropsychology in describing the fragile X premutation phenotype and the role practitioners may have in assessing and monitoring patients with or at risk for neurodegeneration. METHOD: We issued a call for papers for the special issue, highlighting the primary objective of familiarizing clinical neuropsychologists with FXTAS, and with the neuropsychological phenotype of both male and female asymptomatic carriers. RESULTS: Eight papers are included, including an overview of the fragile X-associated disorders (Grigsby), a review of the neuroradiological and neurological aspects of FXTAS and how the disorder compares to other movement disorders (O'Keefe et al.), a perspective on the prominence of white matter disease and dementia in FXTAS (Filley), and a review of mouse models of FXTAS (Foote). There are four research papers, including one on self-reported memory problems in FXTAS (Birch et al.), and three papers focused on the neuropsychiatric aspects of the fragile X premutation, a review (Bourgeois), an examination of autism-related traits (Schneider), and a research paper on executive functioning and psychopathology (Grigsby). CONCLUSIONS: The issue highlights the importance of awareness of fragile X-associated disorders for neuropsychologists, an awareness that must reach beyond neurodevelopmental aspects related to fragile X syndrome into the realm of neurodegenerative disease and aging.
OBJECTIVE: Neuropsychologists have an important role in evaluating patients with fragile X-associated disorders, but most practitioners are unaware of the recently identified neurodegenerative movement disorder known as fragile X-associated tremor ataxia syndrome (FXTAS). The objective of this editorial is to orient the reader to FXTAS and highlight the importance of clinical neuropsychology in describing the fragile X premutation phenotype and the role practitioners may have in assessing and monitoring patients with or at risk for neurodegeneration. METHOD: We issued a call for papers for the special issue, highlighting the primary objective of familiarizing clinical neuropsychologists with FXTAS, and with the neuropsychological phenotype of both male and female asymptomatic carriers. RESULTS: Eight papers are included, including an overview of the fragile X-associated disorders (Grigsby), a review of the neuroradiological and neurological aspects of FXTAS and how the disorder compares to other movement disorders (O'Keefe et al.), a perspective on the prominence of white matter disease and dementia in FXTAS (Filley), and a review of mouse models of FXTAS (Foote). There are four research papers, including one on self-reported memory problems in FXTAS (Birch et al.), and three papers focused on the neuropsychiatric aspects of the fragile X premutation, a review (Bourgeois), an examination of autism-related traits (Schneider), and a research paper on executive functioning and psychopathology (Grigsby). CONCLUSIONS: The issue highlights the importance of awareness of fragile X-associated disorders for neuropsychologists, an awareness that must reach beyond neurodevelopmental aspects related to fragile X syndrome into the realm of neurodegenerative disease and aging.
Entities:
Keywords:
FMR1 gene; FXTAS; dementia; executive function; movement disorder
Authors: D A Hall; E Berry-Kravis; S Jacquemont; C D Rice; J Cogswell; L Zhang; R J Hagerman; P J Hagerman; M A Leehey Journal: Neurology Date: 2005-07-26 Impact factor: 9.910
Authors: D J Allingham-Hawkins; R Babul-Hirji; D Chitayat; J J Holden; K T Yang; C Lee; R Hudson; H Gorwill; S L Nolin; A Glicksman; E C Jenkins; W T Brown; P N Howard-Peebles; C Becchi; E Cummings; L Fallon; S Seitz; S H Black; A M Vianna-Morgante; S S Costa; P A Otto; R C Mingroni-Netto; A Murray; J Webb; F Vieri Journal: Am J Med Genet Date: 1999-04-02
Authors: David Hessl; John M Wang; Andrea Schneider; Kami Koldewyn; Lien Le; Christine Iwahashi; Katherine Cheung; Flora Tassone; Paul J Hagerman; Susan M Rivera Journal: Biol Psychiatry Date: 2011-07-23 Impact factor: 13.382
Authors: Filip Scheperjans; Velma Aho; Pedro A B Pereira; Kaisa Koskinen; Lars Paulin; Eero Pekkonen; Elena Haapaniemi; Seppo Kaakkola; Johanna Eerola-Rautio; Marjatta Pohja; Esko Kinnunen; Kari Murros; Petri Auvinen Journal: Mov Disord Date: 2014-12-05 Impact factor: 10.338
Authors: Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman Journal: Am J Med Genet A Date: 2008-04-15 Impact factor: 2.802
Authors: M A Leehey; E Berry-Kravis; C G Goetz; L Zhang; D A Hall; L Li; C D Rice; R Lara; J Cogswell; A Reynolds; L Gane; S Jacquemont; F Tassone; J Grigsby; R J Hagerman; P J Hagerman Journal: Neurology Date: 2007-12-05 Impact factor: 9.910
Authors: A Puścian; M Winiarski; J Borowska; S Łęski; T Górkiewicz; M Chaturvedi; K Nowicka; M Wołyniak; J J Chmielewska; T Nikolaev; K Meyza; M Dziembowska; L Kaczmarek; E Knapska Journal: Mol Psychiatry Date: 2022-03-30 Impact factor: 13.437